{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:06:17Z","timestamp":1785787577121,"version":"3.56.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2S","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Vaccination in pregnancy with recombinant pertussis vaccine results in similar or higher antibody levels in infants compared with chemically detoxified acellular pertussis vaccine (Tdap\n                      <jats:sub>chem<\/jats:sub>\n                      ). We evaluated antibody responses to primary childhood vaccination in infants born to mothers vaccinated in pregnancy with recombinant pertussis vaccine containing 1, 2 or 5 \u00b5g genetically detoxified pertussis toxin (ap1\n                      <jats:sub>gen<\/jats:sub>\n                      , Tdap1\n                      <jats:sub>gen<\/jats:sub>\n                      , Tdap2\n                      <jats:sub>gen<\/jats:sub>\n                      or TdaP5\n                      <jats:sub>gen<\/jats:sub>\n                      ) or Tdap\n                      <jats:sub>chem<\/jats:sub>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Infants (393) received diphtheria-tetanus-whole cell pertussis (DTwP) at 2, 4 and 6 months (3+0) and 13-valent pneumococcal conjugate vaccine (PCV13) at 2, 4 and 12 months of age (2+1). Serum IgG levels against pertussis toxoid (PT), filamentous hemagglutinin (FHA), diphtheria toxoid (DT), tetanus toxoid (TT), PCV13 serotypes and PT-neutralizing antibody (PT-Nab) titers were assessed. PT-IgG \u226510 IU was used as a cutoff for potential protection in infants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      PT-IgG geometric mean concentrations (GMC) were \u226510 IU\/mL at 5 and 7 months of age but waned below 10 IU\/mL at 13 months in all groups. FHA-IgG GMCs and PT-Nab geometric mean titers were also below 10 IU\/mL in all groups at 13 months of age. TT-IgG and DT-IgG seroprotection rates (\u22650.1 IU\/mL) ranged from 97.1% to 100% at 7 and 13 months. Postbooster PCV13-serotype-specific\n                      <jats:bold>s<\/jats:bold>\n                      eroprotection rates (IgG \u2265 0.35 \u00b5g\/mL) ranged between 87% and 100%. Antibody responses were comparable between groups after DTwP priming (7 months) and PCV13 priming (5 months) and booster vaccination (13 months).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Childhood vaccine responses are comparable after mothers receive genetically or chemically detoxified acellular pertussis vaccines in pregnancy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000004609","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T12:02:15Z","timestamp":1739534535000},"page":"S56-S60","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Infant Responses to Primary Immunization Following Vaccination in Pregnancy With Varying Doses of Recombinant Acellular Pertussis Vaccine Alone or Combined With Tetanus-Diphtheria"],"prefix":"10.1097","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1873-1867","authenticated-orcid":false,"given":"Thanyawee","family":"Puthanakit","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine and Center of Excellence in Pediatric Infectious Diseases and Vaccines, Chulalongkorn University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0140-4600","authenticated-orcid":false,"given":"Kulkanya","family":"Chokephaibulkit","sequence":"additional","affiliation":[{"name":"Siriraj Institute of Clinical Research (SICRES)"},{"name":"Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6965-5537","authenticated-orcid":false,"given":"Suvaporn","family":"Anugulruengkitt","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine and Center of Excellence in Pediatric Infectious Diseases and Vaccines, Chulalongkorn University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3641-7436","authenticated-orcid":false,"given":"Surasith","family":"Chaithongwongwatthana","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1966-7625","authenticated-orcid":false,"given":"Wanatpreeya","family":"Phongsamart","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orasri","family":"Wittawatmongkol","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9439-9152","authenticated-orcid":false,"given":"Supattra","family":"Rungmaitree","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiao","family":"Tang","sequence":"additional","affiliation":[{"name":"PATH, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3978-8208","authenticated-orcid":false,"given":"Chawanee","family":"Kerdsomboon","sequence":"additional","affiliation":[{"name":"BioNet-Asia Co., Ltd., Bangkok, Thailand."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilasinee","family":"Yuwaree","sequence":"additional","affiliation":[{"name":"BioNet-Asia Co., Ltd., Bangkok, Thailand."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Librada","family":"Fortuna","sequence":"additional","affiliation":[{"name":"BioNet-Asia Co., Ltd., Bangkok, Thailand."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souad","family":"Mansouri","sequence":"additional","affiliation":[{"name":"BioNet-Asia Co., Ltd., Bangkok, Thailand."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7679-4802","authenticated-orcid":false,"given":"Hong Thai","family":"Pham","sequence":"additional","affiliation":[{"name":"BioNet-Asia Co., Ltd., Bangkok, Thailand."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niranjan","family":"Bhat","sequence":"additional","affiliation":[{"name":"PATH, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1753-7248","authenticated-orcid":false,"given":"Bruce L.","family":"Innis","sequence":"additional","affiliation":[{"name":"PATH, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"R1-20260413","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1128\/CMR.18.2.326-382.2005","article-title":"Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies.","volume":"18","author":"Mattoo","year":"2005","journal-title":"Clin Microbiol Rev"},{"issue":"12 Suppl 2","key":"R2-20260413","doi-asserted-by":"crossref","first-page":"S310","DOI":"10.1093\/infdis\/jiaa469","article-title":"Pertussis (Whooping Cough).","volume":"224","author":"Decker","year":"2021","journal-title":"J Infect Dis"},{"key":"R3-20260413","article-title":"WHO SAGE pertussis working group Background paper SAGE April 2014."},{"key":"R4-20260413","doi-asserted-by":"crossref","first-page":"S236","DOI":"10.1093\/cid\/ciw559","article-title":"Sustained effectiveness of the maternal pertussis immunization program in England 3 years following introduction.","volume":"63","author":"Amirthalingam","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R5-20260413","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/14760584.2020.1791092","article-title":"A systematic review of the burden of pertussis disease in infants and the effectiveness of maternal immunization against pertussis.","volume":"19","author":"Kandeil","year":"2020","journal-title":"Expert Rev Vaccines"},{"key":"R6-20260413","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/ijgo.15311","article-title":"The current state of pertussis vaccination in pregnancy around the world, with recommendations for improved care: consensus statements from the Global Pertussis Initiative.","volume":"165","author":"Olson-Chen","year":"2024","journal-title":"Int J Gynaecol Obstet"},{"key":"R7-20260413","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/cid\/ciu823","article-title":"Tetanus-diphtheria-pertussis immunization in pregnant women and the prevention of pertussis in young infants.","volume":"60","author":"Cherry","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R8-20260413","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3390\/toxins11100557","article-title":"Pertussis toxin: a key component in pertussis vaccines?","volume":"11","author":"Gregg","year":"2019","journal-title":"Toxins (Basel)"},{"key":"R9-20260413","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/toxins11070373","article-title":"Association of pertussis toxin with severe pertussis disease.","volume":"11","author":"Scanlon","year":"2019","journal-title":"Toxins (Basel)"},{"key":"R10-20260413","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/infdis\/jiy022","article-title":"Maternal vaccination with a monocomponent pertussis toxoid vaccine is sufficient to protect infants in a baboon model of whooping cough.","volume":"217","author":"Kapil","year":"2018","journal-title":"J Infect Dis"},{"key":"R11-20260413","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0264-410X(95)00230-X","article-title":"The effect of formaldehyde, hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodies.","volume":"14","author":"Ibsen","year":"1996","journal-title":"Vaccine"},{"key":"R12-20260413","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1128\/CVI.00561-10","article-title":"Antibodies recognizing protective pertussis toxin epitopes are preferentially elicited by natural infection versus acellular immunization.","volume":"18","author":"Sutherland","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"R13-20260413","doi-asserted-by":"crossref","first-page":"e1161","DOI":"10.1002\/cti2.1161","article-title":"Differences in epitope-specific antibodies to pertussis toxin after infection and acellular vaccinations.","volume":"9","author":"Knuutila","year":"2020","journal-title":"Clin Transl Immunology"},{"key":"R14-20260413","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1056\/NEJMoa1200850","article-title":"Waning protection after fifth dose of acellular pertussis vaccine in children.","volume":"367","author":"Klein","year":"2012","journal-title":"N Engl J Med"},{"key":"R15-20260413","doi-asserted-by":"crossref","first-page":"e20153326","DOI":"10.1542\/peds.2015-3326","article-title":"Waning Tdap effectiveness in adolescents.","volume":"137","author":"Klein","year":"2016","journal-title":"Pediatrics"},{"key":"R16-20260413","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.3389\/fimmu.2019.01344","article-title":"Pertussis prevention: reasons for resurgence, and differences in the current acellular pertussis vaccines.","volume":"10","author":"Esposito","year":"2019","journal-title":"Front Immunol"},{"key":"R17-20260413","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2180-12-61","article-title":"Construction of Bordetella pertussis strains with enhanced production of genetically-inactivated pertussis toxin and pertactin by unmarked allelic exchange.","volume":"12","author":"Buasri","year":"2012","journal-title":"BMC Microbiol"},{"key":"R18-20260413","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s42003-020-01153-3","article-title":"Genetically detoxified pertussis toxin displays near identical structure to its wild-type and exhibits robust immunogenicity.","volume":"3","author":"Ausar","year":"2020","journal-title":"Commun Biol"},{"key":"R19-20260413","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S1473-3099(17)30612-6","article-title":"A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2\/3, randomised controlled non-inferiority trial.","volume":"18","author":"Sricharoenchai","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"R20-20260413","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/S1473-3099(18)30375-X","article-title":"Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2\/3 randomised, controlled, non-inferiority trial.","volume":"18","author":"Pitisuttithum","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"R21-20260413","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/j.vaccine.2021.10.076","article-title":"A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age.","volume":"40","author":"Chokephaibulkit","year":"2022","journal-title":"Vaccine"},{"key":"R22-20260413","doi-asserted-by":"crossref","first-page":"100976","DOI":"10.1016\/j.eclinm.2021.100976","article-title":"Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aP(gen) or combined TdaP(gen) vaccines.","volume":"37","author":"Pitisuttithum","year":"2021","journal-title":"EClinicalMedicine"},{"key":"R23-20260413","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1016\/j.vaccine.2023.06.001","article-title":"A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women.","volume":"41","author":"Puthanakit","year":"2023","journal-title":"Vaccine"},{"key":"R24-20260413","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.vaccine.2023.11.042","article-title":"Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines.","volume":"42","author":"Chokephaibulkit","year":"2024","journal-title":"Vaccine"},{"key":"R25-20260413","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1080\/21645515.2016.1234555","article-title":"Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.","volume":"13","author":"Sirivichayakul","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"R27-20260413","doi-asserted-by":"crossref","first-page":"5998","DOI":"10.1016\/j.vaccine.2016.07.032","article-title":"Guideline for collection, analysis and presentation of safety data in clinical trials of vaccines in pregnant women.","volume":"34","author":"Jones","year":"2016","journal-title":"Vaccine"},{"key":"R28-20260413","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.1016\/j.vaccine.2020.06.050","article-title":"Kinetics of maternal pertussis-specific antibodies in infants of mothers vaccinated with tetanus, diphtheria and acellular pertussis (Tdap) during pregnancy.","volume":"38","author":"Healy","year":"2020","journal-title":"Vaccine"},{"key":"R29-20260413","doi-asserted-by":"crossref","first-page":"102556","DOI":"10.1016\/j.eclinm.2024.102556","article-title":"Safety and immunogenicity of a single dose of Tdap compared to Td in pregnant women in Mali and its effect on infant immune responses: a single-centre, randomised, double-blind, active-controlled phase 2 study.","volume":"71","author":"Haidara","year":"2024","journal-title":"EClinicalMedicine"},{"key":"R30-20260413","doi-asserted-by":"crossref","first-page":"e1087","DOI":"10.1093\/cid\/ciac432","article-title":"Maternal tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccination during pregnancy: impact on infant anti-pertussis antibody concentrations by maternal pertussis priming series.","volume":"76","author":"Havers","year":"2023","journal-title":"Clin Infect Dis"},{"key":"R31-20260413","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/cid\/ciz778","article-title":"Quantity and quality of antibodies after acellular versus whole-cell pertussis vaccines in infants born to mothers who received tetanus, diphtheria, and acellular pertussis vaccine during pregnancy: a randomized trial.","volume":"71","author":"Wanlapakorn","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R32-20260413","doi-asserted-by":"crossref","first-page":"2352909","DOI":"10.1080\/21645515.2024.2352909","article-title":"Antibody persistence to diphtheria toxoid, tetanus toxoid, Bordetella pertussis antigens, and Haemophilus influenzae type b following primary and first booster with pentavalent versus hexavalent vaccines.","volume":"20","author":"Wanlapakorn","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"R33-20260413","year":"2024"},{"key":"R34-20260413","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1097\/INF.0000000000001601","article-title":"Pneumococcal immune response in infants whose mothers received tetanus, diphtheria and acellular pertussis vaccination during pregnancy.","volume":"36","author":"Maertens","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R35-20260413","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/14760584.2020.1749597","article-title":"Immune interference (blunting) in the context of maternal immunization with Tdap-containing vaccines: is it a class effect?","volume":"19","author":"Kandeil","year":"2020","journal-title":"Expert Rev Vaccines"},{"key":"R36-20260413","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.eclinm.2019.06.010","article-title":"The effect of maternal immunisation during pregnancy on infant vaccine responses.","volume":"13","author":"Zimmermann","year":"2019","journal-title":"EClinicalMedicine"},{"key":"R37-20260413","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1016\/j.vaccine.2020.04.001","article-title":"Infant antibody levels following 10-valent pneumococcal-protein D conjugate and DTaP-Hib vaccinations in the first year of life after maternal Tdap vaccination: an open-label, parallel, randomised controlled trial.","volume":"38","author":"Barug","year":"2020","journal-title":"Vaccine"},{"key":"R38-20260413","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1473-3099(17)30654-0","article-title":"Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial.","volume":"18","author":"Goldblatt","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"R39-20260413","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S1473-3099(23)00065-8","article-title":"1 + 1 dose schedule for pneumococcal child vaccination: new normal?","volume":"23","author":"Slotved","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"R40-20260413","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S1473-3099(20)30775-1","article-title":"Immunogenicity of alternative ten-valent pneumococcal conjugate vaccine schedules in infants in Ho Chi Minh City, Vietnam: results from a single-blind, parallel-group, open-label, randomised, controlled trial.","volume":"21","author":"Licciardi","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R41-20260413","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ijid.2020.10.048","article-title":"Pneumococcal disease in Thailand.","volume":"102","author":"Gamil","year":"2021","journal-title":"Int J Infect Dis"},{"key":"R42-20260413","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijregi.2023.06.001","article-title":"Outcomes among Thai children with risk conditions hospitalized for pneumococcal disease (invasive or non-bacteraemic pneumonia): a multi-centre, observational study.","volume":"8","author":"Phongsamart","year":"2023","journal-title":"IJID Reg"},{"key":"R43-20260413","doi-asserted-by":"crossref","first-page":"107047","DOI":"10.1016\/j.ijid.2024.107047","article-title":"Transplacental transfer of maternal antibodies following immunization with recombinant pertussis vaccines during pregnancy: real-world evidence.","volume":"144","author":"Chaithongwongwatthana","year":"2024","journal-title":"Int J Infect Dis"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000004609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:12:16Z","timestamp":1785784336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000004609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":42,"journal-issue":{"issue":"2S","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004609","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}